TGFB1 and neoplasm: TGF-β signaling, a key mediator of tumor–bone interactions, is another promising target, with inhibitors like galunisertib showing reduced metastasis progression in preclinical models, though clinical trials are needed to confirm rib-specific efficacy [28,29].